Merck Sharp & Dohme Corp., Kenilworth, NJ. RATIONALE: MK-7264 is a P2X3 receptor antagonist that has demonstrated reduction in cough frequency in patients with refractory chronic cough (1). We investigated whether therapeutic response to MK-7264 is limited to patients with specific triggers of cough. METHODS: We evaluated a structured medical history questionnaire for refractory and unexplained chronic cough patients participating in a 12-week, randomized, placebo-controlled study of MK-7264 at doses of 7.5, 20, or 50 mg (Smith et al. Am J Respir Crit Care Med (195): Presented at the 2017 ATS Annual Meeting). 'Some of the time to Always' was considered a 'Yes' to a questionnaire item on potential cough triggers; 'Little of the time to Never' was considered 'No.' A post-hoc analysis evaluated the proportion of responders to MK-7264 (ie, reduction from baseline in Awake Cough Frequency [ACF] > 30% at Week 12) according to the 'Yes' or 'No' cough trigger categories. RESULTS: Of 253 randomized patients, 252 reported triggers. The most common questionnaire items leading to a 'Yes' as cough triggers were 'My cough is unpredictable' (79%), 'A tickle in my throat' (73%), and 'An irritation in my throat' (73%), 'Poor Air Quality' (50%) and 'A change in air temperature' (43%). Both non-responders and responders reported a high/similar rate (>80%) of 'Yes' to cough triggers of 'Unpredictable', 'Tickle', and 'Throat Irritation'; a slightly higher rate of non-responders vs. responders reported 'Yes' to 'Poor Air Quality' (88% vs. 65%) and 'Temperature Change' (76% vs. 70%). CONCLUSIONS: Identification of specific triggers appears not to be associated with MK-7264 treatment response. , and Jae-Hyun Lee, MD, PhD 3 ; 1 Gangnam Severance Hospital, Seoul, Korea, Republic of (South), 2 Yonsei University College of Medicine, Seoul, Korea, Republic of (South), 3 Yonsei University College of Medicine, Seoul, Korea. RATIONALE: CD93 has been studied as a novel biomarker for various inflammatory and immune associated diseases, even in asthma recently. We aimed to evaluate the potential role of soluble form of CD93 (sCD93) for allergic asthma. METHODS: We performed house dust mite (HDM) stimulation in BEAS-2B and U937 cell line with and without dexamethasone or against CD93 siRNA treatment. We investigated CD93 expression and level in HDMinduced asthma mouse model. In addition, we conducted post-hoc analysis for the predictive power of sCD93 for asthma using 96 human subjects who were previously studied. RESULTS: BEAS-2B cell stimulated by HDM extract (100 mg) for one hour showed increased mRNA expression of TSLP, IL-33, and CD93. CD93 level in culture supernatants steadily increased for 24 hours after HDM stimulation. Dexamethasone and siRNA (targeting CD93) treatment significantly suppressed it. The siRNA treatment led to increase of IL-6 and TSLP level in culture supernatants, whereas it did not affect IL-33 level. In HDM asthma mouse model, CD93 level decreased in bronchial epithelial cell and lung homogenates; whereas it increased in serum. In human, serum sCD93 level in asthma patients was significantly higher than that in healthy control. When adjusted with age and sex, higher level of serum sCD93 predicts asthma diagnosis with moderate sensitivity (71.4%) and specificity (82.4%) (AUC 5 0.787, P < 0.001). CONCLUSIONS: The level of sCD93 significantly increased after HDM stimulation in vitro and in vivo. We demonstrated potential role of sCD93 as a novel biomarker in allergic asthma. 
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